• News
  • SAN DIEGO
  • BioTech

Isis begins study for cardiovascular disease treatment

Carlsbad-based Isis Pharmaceuticals Inc. (Nasdaq: ISIS) has initiated a Phase 1 clinical study for an anti-sense drug targeting angiopoietin-like 3 protein (ANGPTL3), an independent risk factor for cardiovascular disease.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
46.06
  0.18  
+ 0.39%
2,246,043,000
62.66
22.25

Insider Trade Data

Date Insider Shares Type Value
10/23/2014 Crooke, Stanley T 14,600 Sell $616,412
10/23/2014 Crooke, Stanley T 14,600 Exchange $170,862
10/17/2014 Isis Pharmaceuticals Inc 12,100 Sell $483,939
10/17/2014 Isis Pharmaceuticals Inc 12,100 Sell $483,939
10/03/2014 Crooke, Stanley T 36,000 Sell $1,386,860

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chief Executive Officer, Founder, President, Chairman

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Subscribe Today!